Loading...
•
Dec 31, 2020
Dynavax Q4 2020 Earnings Report
Dynavax reported financial results for the fourth quarter and full year 2020.
Key Takeaways
Dynavax's Q4 2020 total revenues reached $19.6 million, including $13.1 million from net product revenue. The company experienced a net loss of $15.5 million, a decrease from the $36.8 million net loss in Q4 2019. Full year 2020 total revenue was $46.6 million, up from $35.2 million in 2019.
Total revenues for Q4 2020 were $19.6 million, including $13.1 million of net product revenue.
HEPLISAV-B product revenue, net increased to $11.5 million in the fourth quarter of 2020, up from $10.6 million in the same period in 2019.
CpG 1018 product revenue, net was $1.6 million in the fourth quarter of 2020 compared to $0.0 million in the same period in 2019.
Net loss for the fourth quarter of 2020 was $15.5 million compared to a net loss of $36.8 million for the fourth quarter of 2019.
Forward Guidance
Dynavax anticipates first quarter 2021 CpG 1018 revenue to be between $40 million and $60 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...